November 2024 laureates: 10 new projects to be supported by the PSCC

Paris Saclay Cancer Cluster Welcomes 10 New Oncology Projects

The Paris Saclay Cancer Cluster (PSCC) is proud to announce the selection of 10 pioneering oncology projects for its support, bringing the total number of projects accompanied to 60. These projects embody innovation and ambition, leveraging cutting-edge technologies and approaches to tackle some of the most pressing challenges in cancer care.

The new projects include:

• Deeplife: Harnessing multi-omics data, AI, and systems engineering to reverse disease at the molecular level.

• Minos Biosciences: Redefining cell biology research by providing an unprecedented view of cell diversity and dynamics.

• Orinova Therapeutics: Developing gold nanoparticles for precision drug delivery in glioblastoma treatment.

• OncoNext-Remunity: Advancing clinical-stage immunotherapeutics to revolutionize cancer care.

• Odimma Therapeutics: Creating personalized immunotherapies using AI and synthetic DNA technology.

• See2Cure: Innovating fluorescence-guided surgery with diagnostic probes to highlight tumors and reduce relapse risks.

• Stimunity: Developing mRNA-based therapies to stimulate innate immunity through the cGAS pathway.

• Curenetics: Offering an AI-powered tool to personalize cancer treatment decisions.

• React Therapeutics: Developing BCPR inhibitors to enhance cancer treatment efficacy.

• Yomi Pharma: Targeting EGFR-positive tumors with therapies exploiting the unique properties of sortilin protein.

  
  

With this milestone, PSCC reinforces its commitment to accelerating oncology innovations by providing unparalleled access to expertise, infrastructure, and resources.

Are you working on a breakthrough innovation in oncology? Join us in shaping the future of cancer care. https://lnkd.in/eTYvAZV7